AKT1 and hepatocellular carcinoma: Blocking NF-κB and AKT by Hsp90 inhibition sensitized lung adenocarcinoma cells, H23, and hepatocellular carcinoma cells, HepG2, to IAP antagonists resulting in synergistic cancer cell death45.